PCM
PFE icon

Pavaki Capital Management’s Pfizer PFE Stock Holding History

Pavaki Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Hold
12,400
– – 0.1% 111
2026
Q1 		$348K Hold
12,400
– – 0.15% 101
2025
Q4 		$309K Buy
+12,400
New +$313K 0.12% 90

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pavaki Capital Management's PFE Position: Q2 2026 in Review

Pavaki Capital Management held its Pfizer (PFE) position steady in Q2 2026 at 12,400 shares worth $299K. The position accounts for 0.1% of the portfolio, ranked #111.

Pavaki Capital Management first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $348K in Q1 2026. 2,713 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Pavaki Capital Management held 12,400 shares of Pfizer worth $299K as of Q2 2026.
  • Pavaki Capital Management left its Pfizer share count unchanged in Q2 2026.
  • Pfizer made up 0.1% of Pavaki Capital Management's portfolio in Q2 2026, its #111 holding.
  • Pavaki Capital Management first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management's Pfizer position peaked at $348K in Q1 2026.
  • 2,713 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.